Probuphine · DIN 02474921 · 80mg · Subdermal Implant-Kit Pk
Limited Use — Reason for Use code 578 required; Health Canada lists this DIN as Cancelled post market since 2023-06-30 — choose a marketed DIN from the same-category list.Discontinued 2023-06-30 · checked 2026-09-02
StatusLimited Use — Reason for Use code 578 required; Health Canada lists this DIN as Cancelled post market since 2023-06-30 — choose a marketed DIN from the same-category list.
Write on scriptLU code 578 (patient must meet the criteria below); Health Canada lists this DIN as Cancelled post market since 2023-06-30 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 578
Reason for Use code 578
For the management of opioid use disorder in combination with counseling and psychosocial support in adult patients who meet the following criteria:
- The patient is stabilized on a dose of no more than 8mg per day of sublingual buprenorphine for the preceding 90 days; AND
- The patient is under the care of a health care provider with experience in the diagnosis and management of opioid use disorder and has been trained to implant and remove the buprenorphine subdermal implant.
Recommended dose: Four 80mg implants inserted subdermally in the inner side of the upper arm for up to six months.
The maximum quantity that can be claimed per patient is four (4) implant cycles (i.e. two (2) years of therapy).
NOTE: The product monograph indicates that dosing beyond two (2) years cannot be recommended at this time. Probuphine subdermal implants are intended to be in place for six months of treatment. Probuphine implants are removed at the end of the six-month period. If continued treatment is desired, the implants should be replaced by new implants (implanted in the opposite arm) at the time of removal.
Coverage limit:
LU Authorization Period: 2 years
No interchangeable product listed in the Ontario extract
Probuphine · DIN 02474921
Manufacturer: Knight Therapeutics Inc.; listing date 2020-04-30
Health Canada: Cancelled post market since 2023-06-30 · brand PROBUPHINE · ATC N07BC01 BUPRENORPHINE · form Implant · route Subcutaneous · ingredients BUPRENORPHINE HYDROCHLORIDE 80 MG · company Knight therapeutics inc. · schedule Narcotics (cdsa i)
Probuphine: Formulary list price $1495.0000/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1495.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96515 · Verify on the e-Formulary ↗ (DIN 02474921)
Source record
DIN 02474921: Probuphine
Raw flags: sec12=Y, sec3=Y
Item: 280812023; group id 416; item number 1027; lccId 00333; manufacturer id KNT
Source form: Subdermal Implant-Kit Pk; strength: 80mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1495.0000; ministry $1495.0000
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02474921
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96515
Shortage status: discontinued (2023-07-03, reported by KNIGHT THERAPEUTICS INC.); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02474921
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2023-06-30 — choose a marketed DIN from the same-category list.